Molecular dynamics simulations, a leading research tool for discovering and developing targeted protein inhibitors [104], indicated that a lung cancer-associated mutation in the gene of epidermal growth factor receptor (EGFR), resulting in a substitution of Leu 858 to Arg (L858R), can be effectively treated with medicines that bind to EFGR, including luteolin-7-glucoside (72) and epicatechin gallate from V. cinerea because of their superior inhibitory qualities [105]. Here, EGFR is linked to lung carcinoma.